AI summary · may contain errors
Adjuvant nivolumab after upfront surgery did not improve disease-free survival versus observation in resected non-small cell lung cancer, with median 71.3 vs 68.8 months.
- 1 cited this week
- Open access
Moving in Cancer Cell, Cell Reports Medicine, Gut and JAMA.
Rebuilt
AI summary · may contain errors
Adjuvant nivolumab after upfront surgery did not improve disease-free survival versus observation in resected non-small cell lung cancer, with median 71.3 vs 68.8 months.
AI summary · may contain errors
A prospective multiplex immunofluorescence pan-cancer study profiled 2,019 tumors across 14 cancer types, mapping CD8, FOXP3, PD-1, and PD-L1 spatial patterns in the tumor immune microenvironment.
AI summary · may contain errors
Circulating extracellular vesicles enriched for PD-1, PD-L1, and CTLA-4 predict anti-PD-L1 therapy response and survival in advanced hepatocellular carcinoma, with resistance emerging 36–42 weeks before imaging.
AI summary · may contain errors
Pulsed, anaerobe-directed metronidazole combined with anti-PD-1 and a VEGF receptor inhibitor improved progression-free survival in Fusobacterium nucleatum-positive microsatellite-stable metastatic colorectal cancer.
Newest first · last 60 days
AI summary · may contain errors
High baseline neutrophil-to-lymphocyte ratio (NLR) in YL201-treated patients is linked to inferior treatment response and progression-free survival, especially in NSCLC.
AI summary · may contain errors
In resectable non-small cell lung cancer, major pathologic response is linked to spatial enrichment of T- and B-cell activation pathways and CD8+ T-cell infiltration, with an MPR rate of 37.5%.
AI summary · may contain errors
DVD-3E, a protease-activatable logic-gated T cell engager pro-drug, enables conditional IL-2 and TCR cosignaling in solid tumor models, producing potent antitumor responses without systemic toxicity.
AI summary · may contain errors
Neoadjuvant camrelizumab plus apatinib in resectable stage II–IVA HNSCC achieved an overall major pathological response rate of 29.3% (12/41) with low grade ≥3 toxicity (2.4%).
AI summary · may contain errors
Tumor-associated neutrophils sustain splenic myelopoiesis via a self-reinforcing NOX2-ROS/FOXO1/DRP1 circuit that drives GM-CSF-producing progenitors and suppressive myeloid output.
AI summary · may contain errors
Neoadjuvant botensilimab plus balstilimab produced major pathologic responses in resectable non-metastatic colorectal cancer, achieving 41% (95% CI, 21%-64%) in pMMR and 100% (95% CI, 40%-100%) in dMMR.
AI summary · may contain errors
In anti-PD-(L)1 resistant advanced non-small cell lung cancer, ceralasertib plus durvalumab shows modestly higher 24-week durable clinical benefit in KRAS-mutant (37.7%) than KRAS-wild type (29.3%).
AI summary · may contain errors
In a PD1-induced mouse model of immune checkpoint inhibitor-associated myocarditis, AGPAT2 loss increases LPA accumulation that activates LPAR5 to trigger myocardial pyroptosis.
AI summary · may contain errors
Immune checkpoint inhibitor related pituitary toxicity remains a relatively common complication, with diagnostic uncertainty due to subtle presentations and symptom overlap, and no validated biomarker.
AI summary · may contain errors
In 33 patients with Fusobacterium nucleatum–positive, microsatellite-stable metastatic colorectal cancer, tislelizumab plus fruquintinib and metronidazole achieved a median progression-free survival of 6.0 months.
AI summary · may contain errors
In mice with triple-negative breast cancer, personalized cancer cell membrane-derived nanovaccines (CCM/TA-DLNPs) enhance antitumor immunity, reprogram “cold tumor” microenvironments, and improve tumor eradication, recurrence risk, and survival.
AI summary · may contain errors
In the PECATI phase 2 trial for platinum-refractory advanced B3-thymoma and thymic carcinoma, median progression-free survival reached 22.1 months with 88.0% 5-month PFS.
AI summary · may contain errors
In the LCMV chronic infection model, TOX and PD-1 are required to maintain CXCR5+ TCF-1+ CD4 T cell precursors, preserving CD62L+ re-expansion potential.
AI summary · may contain errors
CAR-engineered dendritic cells using CLEC9A or DEC205 intracellular domains enhance antigen uptake and cross-presentation, linked to SYK phosphorylation and stronger antitumor T-cell responses in mouse models.
AI summary · may contain errors
IL-18 depletion in genetically engineered mice with spontaneous pancreatic ductal adenocarcinoma suppresses tumor progression and prolongs survival, linked to STAT1-dependent immune evasion.
AI summary · may contain errors
Lipid-rich malignant ascites suppresses ovarian cancer–associated T-cell function by driving a cholesterol-efflux and incomplete fatty-acid-oxidation transcriptomic program linked to impaired plasma-membrane signaling.
AI summary · may contain errors
Pulsed, anaerobe-directed metronidazole combined with anti-PD-1 and a VEGF receptor inhibitor improved progression-free survival in Fusobacterium nucleatum-positive microsatellite-stable metastatic colorectal cancer.
AI summary · may contain errors
Five tumor DNA-methylation subtypes and a TMC-related five-gene CFISH signature predict overall survival in operable esophageal cancer treated with neoadjuvant ICI-based therapy, including beyond.
AI summary · may contain errors
mRNA-LNP vaccination in an immunocompetent EGFRvIII-driven syngeneic glioblastoma model induces durable EGFRvIII-specific immunity, achieving complete tumor eradication and long-term protection after intracranial rechallenge.
AI summary · may contain errors
IL-8 produced by adult glioblastoma tumor cells instructs monocyte-derived macrophages to suppress healthy T cells, and neutralizing IL-8 restores T cell proliferation.
AI summary · may contain errors
Perioperative camrelizumab plus chemotherapy improved 2-year event-free survival to 77.8% versus 46.1% in resectable stage III–IVB head and neck squamous cell carcinoma.
AI summary · may contain errors
Adoptive transfer of stem-like CD8+ T cells followed by intravenous vaccination prevents immune exclusion in the tumor microenvironment and reprograms tumor cells to upregulate IFN signaling programs.
AI summary · may contain errors
Subcellular spatial redistribution of tumor metabolic components and immune checkpoint molecules creates localized enrichment microdomains and depletion zones that shape immunometabolic crosstalk.
Journals this month
Topics moving, week to 17 Nov 2026
By field